Abstract: Neoplastic meningitis (NM) is a devastating complication of solid tumors with poor outcome. Some randomized clinical trials have been conducted with heterogeneous inclusion criteria, diagnostic parameters, response evaluation and primary endpoints. Recently, the Leptomeningeal Assessment in Neuro-Oncology (LANO) Group and the European Society for Medical Oncology/European Association for Neuro-Oncology have proposed some recommendations in order to provide diagnostic criteria and response evaluation scores for NM. The aim of these guidelines is to integrate the neurological examination with magnetic resonance imaging and cerebrospinal fluid findings as well as to provide a framework for use in clinical trials. However, this composite assessment needs further validation. Since intrathecal therapy represents a treatment with limited efficacy in NM, many studies have been conducted on systemic therapies, including target therapies, with some encouraging results in terms of disease control. In this review, we have analyzed the clinical aspects and the most recent diagnostic tools and therapeutic options in NM.
Introduction
The term neoplastic meningitis (NM), also known as 'leptomeningeal metastasis', refers to the spread of tumor cells to leptomeninges (pia and arachnoid) and subarachnoid space, and their dissemination through the cerebrospinal fluid (CSF). An increased incidence of NM has occurred because of the development of effective antineoplastic treatments for solid tumors and improvement of diagnosis on magnetic resonance imaging (MRI). 1 The majority of the antineoplastic drugs are able to control the systemic disease, but do not penetrate an intact blood-brain barrier (BBB) in adequate concentrations, thus the central nervous system (CNS) is a frequent site of relapse. NM is the third most common CNS complication of cancer following brain metastases and epidural spinal cord compression, and represents a challenge for clinicians in terms of diagnosis and treatment.
For a long time, diagnostic tools for NM were not standardized and there were no generally accepted criteria to define patient subgroups that might benefit from therapy. Recently, the Leptomeningeal Assessment in Neuro-Oncology (LANO) Group and the European Association for Neuro-Oncology/ European Society for Medical Oncology (EANO/ ESMO) have proposed clinical and radiological recommendations 2, 3 in order to provide diagnostic and response criteria for NM, both for enrollment in clinical trials and in clinical practice.
Treatment of NM aims to improve neurological symptoms and extend overall survival (OS), especially when the disease is diagnosed early on. Currently, there is not a standard treatment and several approaches, such as radiotherapy (RT), intrathecal or systemic therapies, can be employed. Despite these aggressive therapeutic options, the median overall survival (OS) is poor and ranges between 6 and 8 weeks without tumorspecific treatments, while it may be prolonged to 3-6 months with NM-directed therapies, including target therapies and immunotherapy as well. 4 In this review, we analyzed the clinical aspects and the most recent diagnostic tools and therapeutic options in NM.
Epidemiology
NM is a frequent complication in patients with solid tumors (4-15%) as well as in patients with lymphoma or leukemia. 5, 6 The most common primary tumors metastasizing to the leptomeninges are breast and lung carcinomas, melanoma, aggressive non-Hodgkin lymphoma, and acute lymphocytic leukemia. Because of the improved efficacy of antineoplastic treatments, there is an increased number of NM from solid tumors that were rarely associated with NM in the past, such as prostate, ovarian, gastric, cervical, and endometrial cancers. 7 Furthermore, NM is diagnosed in 1-2% of patients with primary brain tumors, such as ependymomas, medulloblastomas, germinomas and gliomas. 8 In more than 70% of patients NM develops in the setting of an active systemic disease, while in 20% of patients it occurs in association with a stable disease, and in up to 10% of patients it is the first manifestation of cancer.
Some risk factors for developing NM have been recognized: concomitant brain metastases are associated with NM in 33-54% of patients with breast cancer, 56-82% with lung cancers and 87-96% with melanomas. [9] [10] [11] Within breast cancers, the lobular subtype, triple-negative or human epidermal growth factor receptor-2 (HER2) subtypes display a specific tropism for CNS, 12, 13 as well as the expression of the mutant epidermal growth factor receptor (EGFR) 14 or the anaplastic lymphoma kinase (ALK) rearrangement in non-small-cell lung cancer (NSCLC). 15, 16 To date, both mutations are targeted by EGFR tyrosine kinase inhibitors (TKIs) and ALK inhibitors, respectively, with encouraging data regarding disease control. Conversely, the role of risk factors (i.e. BRAF mutation) in patients with melanoma and NM has been investigated in a few large cohorts without any relevant evidence.
Surgery may be a factor influencing the leptomeningeal dissemination: in particular, the opening of the ventricular system during resection of a brain metastasis (BM) or primary brain tumor can be associated with CSF spreading, especially in posterior fossa lesions and when using a piecemeal compared with en-block resection. 17, 18 Moreover, the incidence of NM seems higher in patients treated with surgery followed by stereotactic radiosurgery compared with radiosurgery alone. 19 
Pathogenesis
Tumor cells may reach the subarachnoid space by means of a hematogenous spread through the venous or arterial circulation, a growth along nerve and vascular sheaths, a migration from a tumor adjacent to CSF, or by a iatrogenic spread following resection of a BM. 20, 21 Tumor cells may disseminate through the CSF along the entire CNS with a predilection to invade regions with slow CSF flow or gravity-dependent sites, such as basal and lumbar cisterns or posterior fossa. Recent data suggest that the increased activity of some matrix metalloproteases, including matrix metalloproteasis 9 (MMP-9) and the A disintegrin and metalloproteasis 8 and 17 (ADAM8 and ADAM17), may play a role in malignant invasion in the CSF. 22 
Diagnosis
Clinical manifestations of NM are typically multifocal and may involve one or more segments of the neuroaxis: cerebrum (15%), cranial nerves (35%), or spinal cord (50%). 7 Clinicians need to be careful in the evaluation of a patient with suspected NM because any site in the CNS could be potentially involved, and signs and symptoms may overlap with those of parenchymal brain metastases or mimic treatment-related toxicities and, rarely, neurological paraneoplastic syndromes.
The most common clinical presentations are as follow: Other important aspects are the neurocognitive functions and the self-perception of quality of life: in this regard, the patient-reported outcomes (PROs) and performance status could be prognostic indicators of both progression-free survival (PFS) and OS in patients with primary and metastatic brain tumor. 25 Some experts have proposed adding the MD Anderson Cancer Center Symptom Inventory Brain Tumor Module (MDASI-BT) and Spine Tumor Module (MDASI-ST) to better define symptoms, such as pain or incontinence, which otherwise would not be easily detected. 2 Although there is a lack of validated data in the literature, it would not be surprising if both quality-of-life measures and neurological examination provide additional insights regarding treatment response and tolerability of treatments.
Neuroimaging assessment
Brain and spinal cord MRI without and with contrast enhancement, using at least 1.5 Tesla field strength, is highly recommended for the neuroradiological assessment in suspected NM. 26 Contrast-enhanced T1-weight and fluid-attenuated inversion recovery (FLAIR) sequences are the most sensitive to show NM lesions. 27 Contrast brain and spinal cord MRI must be performed at baseline and following treatments.
The neuroradiological diagnosis in NM is challenging and MRI in some patients may be negative. Sensitivity and specificity of brain and spinal cord MRI have not been fully investigated so far, due to the limited number of publications, but it has been estimated in the range of 66-98% and 77-97.5%, respectively. 28,29 Pauls and coworkers reported a higher sensitivity of contrast-enhanced T1 imaging in detecting NM from solid tumors compared with hematological malignancies. 30 Moreover, the MRI sensitivity is superior in NM from solid tumors with elevated CSF cell counts in comparison to those with normal CSF counts. 31 Linear or nodular enhancing lesions of the cranial nerves and spinal nerve roots (e.g. cauda equine), brain sulci and cerebellar foliae are the most common findings 32, 33 ( Figures 1-3 ). NM lesions typically are small in size (<5 mm) and with complex geometry, thus a quantitative analysis with current MRI technology is difficult. 34 Other neuroimaging techniques (MRI spectroscopy, MRI perfusion, MRI diffusion and positron emission tomography) are not currently employed. Communicating hydrocephalus could be observed in 11-17% of patients, and CSF flow studies, including radioisotope cisternography, are useful in the case of suspected CSF blockage or altered intrathecal drug delivery. 35, 36 The LANO Group recommends for clinical trials that measurable lesions are defined as nodules of at least 5 × 10 mm in the orthogonal diameters and should be distinguished from linear contrast enhancement. Up to five target lesions (either measurable or not measurable) are selected at the baseline and must be monitored during the follow up. Based on the current recommendations, response determination in NM is as follows: completely resolved (+3), definitely improved (+2), possibly improved (+1), unchanged (0), possibly worse (−1), definitely worse (−2), new site of disease (−3). An increase of over 25% in a measurable lesion compared with the baseline is necessary to declare a progressive disease; similarly, a decrease of over 50% in a measurable lesion is considered as a partial response. The complete disappearance of a lesion is classified as complete response. All other situations are considered as stable disease. Changes of the ventricular volumes are not considered in the response assessment as well as the use of corticosteroids, which only modestly affect neurological improvement or MRI enhancement in NM from solid tumors. Conversely, the oncolytic effect of steroids in hematologic cancers is well known and thus steroid dose is included in the response criteria. 2 The EANO/ESMO Group has proposed a classification of the radiological findings in NM: linear leptomeningeal disease (type A), nodular leptomeningeal disease (type B), both linear and nodular leptomeningeal disease (type C), absence of enhanced lesions but presence of hydrocephalus (type D)
CSF analysis
Several alterations may be found in the CSF of patients with NM, and include increased pressure (>200 mm H 2 0) in 21-42% of patients, elevated leucocyte count (>4/mm 3 ) in 48-77.5%, high level of proteins (>50 mg/dl) in 56-91% and decreased level of glucose (<60 mg/dl). Moreover, an increased level of lactate dehydrogenase (>1.6 mEq/liter) may be detected, while the presence of oligoclonal bands indicates an intrathecal immune activation. 38 All these findings are not pathognomonic of NM, and the identification of malignant cells in the CSF remains the 'gold standard' for diagnosis.
CSF cytology is usually a qualitative analysis with low sensitivity, and up to 30-50% of patients have a negative CSF. 39 If the first CSF analysis is negative, a second or third lumbar puncture should be carried out with an increase of sensitivity to 80%. 3 Notably, some factors may impact the yield of CSF cytology, such as volume of CSF (at least 10 ml), site of sample collection (that should be close to the neuroimaging alterations), and time to process CSF (within 30 min). 31, 40 Overall, the interpretation of CSF cytology, according to the LANO Group recommendations, is as follows: positive: unequivocal presence of neoplastic cells; equivocal: presence of 'atypical' or 'suspicious' cells; negative: absence of neoplastic cells.
A critical point is the duration of response following antineoplastic treatments: importantly, to declare a cytological response, CSF must be cleaned of tumor cells and maintain the status for at least 4 weeks, and other parameters, such as proteins, cell count and glucose level, are not taken into consideration for the evaluation of response.
Based on these criteria, progressive disease is defined by either conversion of negative to positive CSF cytology or failure to convert positive cytology to negative (refractory disease) following induction therapy.
The role of CSF FC in diagnosis of NM from solid tumors is limited, as reported by the LANO Group guidelines. In this regard, there is not a standard CSF FC diagnostic test to distinguish neoplastic cells from reactive pleocytosis in cases of doubtful morphology on conventional CSF cytology. 41 Conversely, the CSF FC is a highly sensitive quantitative analysis for the diagnosis of NM hematologic malignancies as it may allow a more objective determination of tumor burden 42 and predict the risk of CNS relapse. 43, 44 Recently, the EANO/ESMO Group provided recommendations considering both CSF and neuroimaging findings. 3 The aim was twofold: to provide standardized diagnostic criteria and treatment response parameters shared by all clinicians; and to enroll in clinical trials patients who fulfill prespecified inclusion criteria.
Future directions in the CSF diagnosis
The liquid biopsy could be a new approach for an early diagnosis and monitoring of NM. Genomic profiles of circulating tumor cells (CTCs) in the CSF have been shown to closely match those of the corresponding tumors. 45 CSF samples from patients diagnosed with NM have been analyzed for the expression of epithelial cell adhesion molecules (EpCAM) to identify the CTCs. The prognostic value of FC immunophenotyping was evaluated in 72 patients diagnosed with NM and eligible for therapy. 46 Compared with cytology, FC immunophenotyping had greater sensitivity and negative predictive value (80% versus 50% and 69% versus 52%, respectively), but lower specificity and positive predictive value (84% versus 100% and 90% versus 100%, respectively). Moreover, the multivariate analysis revealed that the percentage of CSF EpCAM-positive cells predicted an increased risk of death. In another study, EpCAM-based FC showed 100% sensitivity and 100% specificity rates in detecting NM compared with a sensitivity rate of 61.5% for cytology. 47 This study may overestimate the accuracy: in fact, other studies reported lower sensitivity and specificity rates. [48] [49] [50] Cordone and coworkers reported the successful use of CSF FC in detecting the overexpression of MUC-1 (CD227) and syndecan-1 (CD138), which are strongly correlated with CSF dissemination from breast cancer. Considering the small sample size, validation in a large cohort of patients is needed to confirm these results. 51 Overall, the results suggest that CSF FC warrants further investigation for diagnosing NM. A further improvement in diagnosis is the Rare Cell Capture Technology (RCCT) for detecting and numbering CTCs in the CSF: Lin and colleagues defined at least one CSF-CTC/ml as the optimal cutoff for a robust diagnosis of NM. 52
Circulating tumor DNA (ctDNA) has also been the objective of investigations in terms of liquid biopsy for brain tumors. Craniospinal RT is not recommended because of the poor benefit and the significant risk of developing severe adverse effects (myelotoxicity, enteritis and mucositis).
Intrathecal chemotherapy. Intrathecal treatment offers the advantage of a local therapy with minimum systemic toxicity. Although high drug concentrations can be achieved in the CSF, intrathecal treatment is not effective for bulky disease in the meninges because intra-CSF agents penetrate only 2-3 mm into such lesions. 68 Chemotherapy administration can be performed either via lumbar puncture or via an intraventricular device with a catheter into the lateral ventricle and an Ommaya reservoir. The safety of ventricular devices has been shown in several series, but the management of the device could be difficult, and careful handling is required to avoid infections or obstruction. 69 Three drugs are commonly used for the intrathecal treatment of NM: methotrexate (MTX), cytarabine (Ara-C) and thioTEPA. Different schedules have been proposed without any consensus on optimal dose, frequency of administration, or duration of treatment. Most patients are treated until progression and no advantage in terms of radiological control of the disease has been reported when comparing the three drugs. 70, 71 Due to the short half life of MTX, Ara-C, and thioTEPA (range 4.5-8.0 h), multiple weekly injections are necessary to maintain cytotoxic CSF level. In this regard, liposomal cytarabine (median half life 336 h) every 14 days may provide longer time to neurological progression compared with patients treated with MTX, 71 and reduce the discomfort for patients of multiple lumbar punctures.
There is some clinical evidence that intrathecal chemotherapy may improve disease control and survival in NM from solid tumors, especially in patients with favorable prognostic factors, such as younger age (<55 years), absence of systemic metastases or cranial nerve involvement, normal value of CSF glucose and proteins. Moreover, the treatment response seems to be more dependent on the pretreatment patient characteristics than on the type of treatment. 72 Overall, the evidence of the efficacy of intrathecal therapy is low and a careful evaluation of clinical factors helps clinicians to identify the subgroups of patients who may benefit. Some driver mutations, such as EGFR mutations (11% of white patients with NSCLC) and ALK rearrangements (5% of NSCLC) 74 may be targeted by specific inhibitors with encouraging data regarding disease control. The presence of EGFR mutations is an early step during carcinogenesis in NSCLC, and both BM and leptomeningeal dissemination are more common in patients with EGFR mutation compared with those who are EGFR wild type . 75, 76 Liao and colleagues have shown the efficacy of the firstgeneration EGFR TKI compounds, such as erlotinib and gefitinib, in NM from patients with EGFR mutation and longer OS (10.9 months versus 2.3 months). 77 However, a low level (1-3%) of EGFR TKIs can be found in the CSF, suggesting an inability to adequately penetrate the BBB. Thus, higher doses of either erlotinib 78 or gefitinib 79 have been administered in order to achieve adequate therapeutic concentrations, reporting a neurological improvement in 57% and 50% of NM, and modest benefit in terms of median OS (3.5 months versus 6.2 months). Moreover, erlotinib has shown higher CSF concentrations (28.7 versus 3.7 ng/ml) 80 and cytologic conversion rates (64.3% versus 9.1%) 81 compared with gefitinib. Despite no improvement in OS, high doses of erlotinib have been suggested as palliative care to control neurological symptoms from NM.
Afatinib is an irreversible second-generation EGFR TKI that has demonstrated a good profile of efficacy in NM or BM in patients whose condition has failed to respond to first-line TKIs. Overall, 35% of patients achieved a radiological response, but the study did not distinguish the outcome between BM and NM. 82 Notably, the penetration rate of afatinib in the CSF is 1.65% with a significant efficacy in patients with uncommon EGFR mutations, such as exon 18 mutations. 83 8 journals.sagepub.com/home/tan From 49% to 63% of patients with NSCLC developed resistance to first-and second-generation EGFR TKIs due to the presence of a threonine-methionine substitution at position 790 (T790M) in exon 20. In this regard, osimertinib (AZD9291), a third-generation EGFR TKI, has shown greater penetration and better control of the extra cranial disease, 84 while an ongoing phase II trial [ClinicalTrials.gov identifier: NCT0222-8369] with this drug is enrolling T790M-positive patients with NSCLC and NM.
A new promising therapeutic option is represented by AZD3759, a novel EGFR TKI with an excellent BBB penetration which is active against EGFR mutations, with the exception of T790M mutation. The efficacy and tolerability of AZD3759 have been investigated in 29 patients in the BLOOM trial. Of the four patients with NM who were enrolled, three displayed a significant reduction of EGFR expression on the cell surface, and one patient had a CSF conversion in two consecutive samples. 85 In animal models the anti-VEGF (vascular endothelial growth factor) A agent bevacizumab prevents the formation of NSCLC brain metastases. 86 Based on this background, some phase II trials have reported an improved OS with the combinations erlotinib-bevacizumab 87 and gefitinib-bevacizumab, 88 and an ongoing clinical trial [ClinicalTrials.gov identifier: NCT02803203] is now evaluating the efficacy of osimertinib-bevacizumab in NM from NSCLC.
ALK rearrangement is found in only 4-5% of patients with NSCLC and CNS is a relapse site in 35-50% of patients. NM in patients with ALKpositive NSCLC tends to appear later on (approximately 9 months from the diagnosis of NSCLC), suggesting that it is a late complication. 89 Two randomized phase II trials have reported a major benefit from the first-generation ALK inhibitor crizotinib in terms of disease control in BM of patients with ALK mutation, 89, 90 but the efficacy is still controversial in NM due to the poor CNS penetration.
The second-generation ALK inhibitors, including ceritinib and alectinib, have been approved for the treatment of patients who are ALK positive, who were resistant to crizotinib. The phase II ASCEND-2 trial has demonstrated the efficacy of ceritinib in BM, 91 Secondary ALK kinase domain mutations, including the recalcitrant G1202R mutation, have been identified in patients whose disease progressed on ceritinib or alectinib after crizotinib therapy. Brigatinib, an investigational nextgeneration ALK TKI, was designed for the potent activity against a broad range of ALK resistance mutations. 95 Recently, Kim and collaborators reported some benefits in terms of radiological response (54%) and median PFS (12.9 months) following brigatinib in 154 BM from crizotinibrefractory ALK-positive NSCLC. 96 However, there are no data available in NM.
Lorlatinib is a new third-generation ALK inhibitor, designed specifically to improve CNS penetration in crizotinib-resistant patients. 97 A phase I trial of 54 patients has demonstrated impressive disease control in patients with ALK-and ROS1-positive NSCLC and BM; to date, an ongoing phase II trial [ClinicalTrials.gov identifier: NCT01970865] is evaluating the activity of lorlatinib in both BM and NM.
Some preliminary data are available regarding the efficacy and tolerability in BM of immunotherapy, including anti-programmed cell death 1 (PD-1) compounds, such as nivolumab, 98 pembrolizumab, 99 or the anti-PD ligand 1 atezolizumab, 100 but there are no data in NM.
A new attractive therapeutic option is the oligodeoxynucleotide containing unmethylated cytosineguanosine motifs (CpG-ODN), that may activate both the innate and the adaptive immune system through toll-like receptor 9 (TLR-9). 101 CpG-28 (TLR-9 agonist) may induce tumor reduction, especially when inoculated directly into the tumor in experimental models. 102, 103 Based on this background, a phase I trial was designed to define the safety profile of CpG-28 in 29 patients with NM from different metastatic tumors, including journals.sagepub.com/home/tan 9 NSCLC. CpG-28 was well tolerated both subcutaneously and intrathecally. Interestingly, the median OS was slightly higher in eight patients who were concurrently treated with bevacizumab, but the difference was not statistically significant (19 weeks versus 15 weeks). 104 Neoplastic meningitis from breast cancer. Breast cancer is the most frequent cause of NM from solid tumors, with an estimated frequency of 3-5%. Capecitabine has shown long-lasting responses in NM in small case series, 105 and the use of an intensified regimen, such as metronomic schedule, has been proposed to treat NM from breast cancer, and is planned to be investigated in a larger phase II trial. 106 Amplification of HER2 is observed in 15-20% of patients with breast cancer. Although HER2 is not identified as a risk factor in NM, brain metastases occur more frequently in HER2-positive breast cancer. Since trastuzumab does not easily cross the BBB, intrathecal trastuzumab has been investigated. Few reports in the literature have described clinical and radiological responses following intrathecal trastuzumab. [107] [108] [109] Seventeen patients, who were administered intrathecal trastuzumab, displayed a significant neurological improvement and a CSF conversion in 66.7%, a PFS of 7.5 months and a median OS of 13.5 months, 110 suggesting that intrathecal trastuzumab could be a feasible therapeutic option.
Lapatinib is a HER1-2 TKI that plays a significant role as a second-line treatment in BM from HER2-positive breast cancer following trastuzumab failure. 111 A single-arm phase II trial (LANDSCAPE) has shown the activity of the combination of lapatinib and capecitabine as a first-line treatment in brain metastases from HER2-positive breast cancer. 112 Conversely, no significant differences between capecitabine plus lapatinib versus capecitabine plus trastuzumab were observed in terms of incidence of CNS metastases as first site of relapse. 113 Lavaud and coworkers suggested that high doses of oral lapatinib may be more effective than other intrathecal drugs, but this hypothesis needs to be further investigated in larger series. 114 Neratinib is an irreversible inhibitor of HER2, erbB4 and EGFR with increased ability to cross an intact BBB and is unaltered by ABCB1-B2 transporters. However, the activity on BM does not seem superior over that of lapatinib. 115 Finally, there are no data available on the efficacy and safety of lapatinib, neratinib, trastuzumab emtansine, or pertuzumab in NM from HER2-positive breast cancer.
Neoplastic meningitis from melanoma.
Traditional chemotherapies, including temozolomide or nitrosoureas (dacarbazine and fotemustine), have limited efficacy in BM or NM from melanomas. Checkpoint inhibitors, such as nivolumab, 116 ipilimumab, 117 and pembrolizumab, 118 alone or in combination with other treatments, have changed the prognosis of metastatic melanomas achieving a median OS ranging from 7.5 months to 22.7 months. 119 A similar trend was observed with BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib) in BM from melanomas with a surprisingly OS of more than 5 years. 120 Few case reports are present in the literature regarding the efficacy of vemurafenib in NM from melanomas. 121, 122 However, vemurafenib has a limited penetration of the BBB, suggesting a low chance to control the NM disease. 123 
Conclusion
NM from solid tumors is an emerging complication with no effective therapies. Great efforts have been made to provide standardized diagnostic criteria and methods of response evaluation for patients with NM, which require further testing and validation. Similarly, promising new techniques may play a role in the early detection of NM. Finally, randomized clinical trials with adapted methodology and new inclusion criteria are needed to better define the role of novel therapeutic options in NM.
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